Brief: Acer Therapeutics Announces Agreement With FDA On Special Protocol Assessment For Its Phase 3 EDSIVO™ (Celiprolol) Trial In Vascular Ehlers-Danlos Syndrome Patients
09/05/2022 14:00
May 9 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ANNOUNCES AGREEMENT WITH FDA ON SPECIAL
PROTOCOL ASSESSMENT FOR ITS PHASE 3 EDSIVO™ (CELIPROLOL) TRIAL
IN VASCULAR EHLERS-DANLOS SYNDROME PATIENTS
* ACER THERAPEUTICS ANNOUNCES AGREEMENT WITH FDA ON SPECIAL
PROTOCOL ASSESSMENT FOR ITS PHASE 3 EDSIVO™ (CELIPROLOL) TRIAL
IN VASCULAR EHLERS-DANLOS SYNDROME PATIENTS
* ACER THERAPEUTICS INC - DURATION OF DISCOVER TRIAL IS
CURRENTLY
ESTIMATED TO BE APPROXIMATELY 3.5 YEARS TO COMPLETION
Source text for Eikon: ID:nGNXbMLcC6
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31